Last reviewed 2026-05-18 · How we verify

ACH-0145228: Immediate Release

Alexion Pharmaceuticals, Inc. · Phase 1 active Small molecule Quality 0/100

ACH-0145228: Immediate Release is a Small molecule drug developed by Alexion Pharmaceuticals, Inc.. It is currently in Phase 1 development. Also known as: ALXN2050.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ACH-0145228: Immediate Release
Also known as	ALXN2050
Sponsor	Alexion Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ACH-0145228: Immediate Release CI brief — competitive landscape report
ACH-0145228: Immediate Release updates RSS · CI watch RSS
Alexion Pharmaceuticals, Inc. portfolio CI

Frequently asked questions about ACH-0145228: Immediate Release

What is ACH-0145228: Immediate Release?

ACH-0145228: Immediate Release is a Small molecule drug developed by Alexion Pharmaceuticals, Inc..

Who makes ACH-0145228: Immediate Release?

ACH-0145228: Immediate Release is developed by Alexion Pharmaceuticals, Inc. (see full Alexion Pharmaceuticals, Inc. pipeline at /company/alexion-pharmaceuticals-inc).

Is ACH-0145228: Immediate Release also known as anything else?

ACH-0145228: Immediate Release is also known as ALXN2050.

What development phase is ACH-0145228: Immediate Release in?

ACH-0145228: Immediate Release is in Phase 1.

Manufacturer: Alexion Pharmaceuticals, Inc. — full pipeline
Also known as: ALXN2050

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing